Showing 2161-2170 of 10595 results for "".
Why Consider Lasers?
https://practicaldermatology.com/topics/practice-management/why-consider-lasers/18863/Should younger dermatologists add devices to their practice? Laser expert Eric Bernstein, MD talks about the decision to embrace technology and explains how it can mold the future of those who have a passion for lasers and other energy-based devices. Watch other PD Asks videos with Eric BernsteinDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatThe Treatment Landscape for Children and Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37153/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, provides an overview of current therapeutic options for pediatric atopic dermatitis patients.Clinical Questions About Isotretinoin and More
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/clinical-questions-about-isotretinoin-and-more/54661/Lawrence Eichenfield, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.Updates on Psoriasis Biologics
https://practicaldermatology.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.Cutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.Noah Worcester 2024: Dr. Cohen on Lasers
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-cohen-lasers/24578/Joel L. Cohen, MD, FAAD, summarizes his lecture on laser resurfacing and perioral rejuvenation at the 2024 Noah Worcester Dermatological Society meeting.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments i